Chasing Pfizer, GSK’s 5-in-1 meningococcal vaccine delivers phase 3 trial win
March 16, 2023
Source: drugdu
86
Nearly three years after dosing the first patient in a phase 3 trial, GSK has now reported positive results from the trial of its much-anticipated combination meningitis vaccine.
The shot, a combination of GSK's approved vaccines Bexsero and Menveo, targets meningitis and blood poisoning caused by the A, B, C, W, and Y groups of meningococcal bacteria.
The serogroups A, B, C, W and Y cause nearly all invasive meningococcal disease (IMD) cases globally, GSK said in a statement. As it stands now in the U.S., protection from all five groups requires four injections from two separate vaccines.
But GSK is looking to change that with its two-dose shot, which is administered six months apart.
GSK said that the vaccine candidate met endpoints in the trial, which enrolled healthy people between 10 and 25 years of age. The vaccine matched up to Bexsero and Menveo, eliciting a “clinically meaningful immune response.”
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Pioneer Institute study finds IRA discourages non-opioid drug innovation May 3, 2024
- Ono Pharmaceutical acquires cancer-focused biopharma Deciphera for $2.4bn May 3, 2024
- New study reveals global risk distribution of visceral leishmaniasis May 3, 2024
- Genetic associations of key genes in breast cancer pathogenesis May 2, 2024
- Medtronic wins FDA approval for Inceptiv closed-loop spinal cord stimulator May 2, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
